Strategy for post-Brexit life science sector unveiled
Plan aims to solve long-standing issue of access to medicines
Richard Staines
Accelerated Access Review, Brexit, market access, policy, politics, UK life sciences industrial strategy
0 Comment
Plan aims to solve long-standing issue of access to medicines
Digital and Social Media/ News/ UK & Europe
Marco Ricci
Accelerated Access Review, digital health, NHS
0 Comment
New £86 million fund aims to speed up patient access to innovative digital technologies.
Richard Staines
Accelerated Access Review, NICE, policy, regulation
0 Comment
Proposals fall short of ambitions of Accelerated Access Review.
Richard Staines
Accelerated Access Review, Brexit, finance, market access, NICE, policy
0 Comment
Big pharma could take its money elsewhere post Brexit, report warns.
AstraZeneca/ News/ UK & Europe
Richard Staines
Accelerated Access Review, AstraZeneca, cancer, lung cancer, NICE, R&D
0 Comment
Richard Staines
Accelerated Access Review, cost-effectiveness, NICE, pricing, regulation, reimbursement, Wellcome Trust
0 Comment
NICE, regulator and NHS should work together, according to review.
Pharma Market Access/ Sales and Marketing/ UK & Europe/ Views and analysis
Andrew McConaghie
AAR, Accelerated Access Review, market access, NHS England, UK
0 Comment
What can the AAR do for the UK pharma industry, the health service and patients?
Articles/ Pharma Market Access/ Views and analysis
Linda Banks
Accelerated Access Review, market access, NICE
0 Comment
Articles/ UK & Europe/ Views and analysis
Leela Barham
Accelerated Access Review, Leela Barham
0 Comment